{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T06:33:47Z","timestamp":1790145227958,"version":"4.0.1"},"reference-count":54,"publisher":"Elsevier BV","issue":"31","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.vaccine.2019.06.039","type":"journal-article","created":{"date-parts":[[2019,6,25]],"date-time":"2019-06-25T20:27:43Z","timestamp":1561494463000},"page":"4246-4255","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["An indirect comparison meta-analysis of AS03 and MF59 adjuvants in pandemic influenza A(H1N1)pdm09 vaccines"],"prefix":"10.1016","volume":"37","author":[{"given":"Michael I.","family":"Hauser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2391-4396","authenticated-orcid":false,"given":"David J.","family":"Muscatello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annabel C.Y.","family":"Soh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic E.","family":"Dwyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin M.","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.vaccine.2019.06.039_b0005","first-page":"2596","article-title":"Readiness for responding to a severe pandemic 100 years after 1918","volume":"187","author":"Jester","year":"2018","journal-title":"Am J Epidemiol"},{"issue":"1","key":"10.1016\/j.vaccine.2019.06.039_b0010","doi-asserted-by":"crossref","first-page":"187","DOI":"10.20506\/rst.28.1.1879","article-title":"Pandemic influenza\u2013including a risk assessment of H5N1","volume":"28","author":"Taubenberger","year":"2009","journal-title":"Rev Sci Tech"},{"key":"10.1016\/j.vaccine.2019.06.039_b0015","unstructured":"World Health Organization. A checklist for pandemic influenza risk and impact management: building capacity for pandemic response. Geneva: World Health Organization; 2018. Available at: http:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/259884\/9789241513623-eng.pdf;jsessionid=CD2ECB235CE943ED4F60FE6C0A14D90C?sequence=1 [accessed Sept 22, 2018]."},{"key":"10.1016\/j.vaccine.2019.06.039_b0020","first-page":"CD001269","article-title":"Vaccines for preventing influenza in healthy adults","volume":"2","author":"Demicheli","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.vaccine.2019.06.039_b0025","unstructured":"World Health Organization. Influenza vaccine response during the start of a pandemic: report of the second WHO informal consultation held in Geneva, Switzerland, 21\u201322 July 2016, Geneva: World Health Organization; 2017. Available at: http:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/254743\/WHO-HSE-PED-GIP-EPI-2017.1-eng.pdf?sequence=1 [accessed Sept 22, 2018]."},{"issue":"45","key":"10.1016\/j.vaccine.2019.06.039_b0030","doi-asserted-by":"crossref","first-page":"5410","DOI":"10.1016\/j.vaccine.2016.08.019","article-title":"The 2015 global production capacity of seasonal and pandemic influenza vaccine","volume":"34","author":"McLean","year":"2016","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2019.06.039_b0035","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1038\/nm.3409","article-title":"Key roles of adjuvants in modern vaccines","volume":"19","author":"Reed","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2019.06.039_b0040","first-page":"323","article-title":"Adjuvants for pandemic influenza vaccines","volume":"333","author":"Atmar","year":"2009","journal-title":"Curr Top Microbiol Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2019.06.039_b0045","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1001\/jama.2015.7916","article-title":"Effect of varying doses of a monovalent H7N9 influenza vaccine with and without AS03 and MF59 adjuvants on immune response: a randomized clinical trial","volume":"314","author":"Jackson","year":"2015","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.vaccine.2019.06.039_b0050","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1750-2659.2011.00229.x","article-title":"Immunogenicity and safety of pandemic influenza A (H1N1) 2009 vaccine: systematic review and meta-analysis","volume":"5","author":"Yin","year":"2011","journal-title":"Influenza Other Respir Viruses"},{"issue":"5","key":"10.1016\/j.vaccine.2019.06.039_b0055","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1093\/infdis\/jir641","article-title":"Safety and long-term humoral immune response in adults after vaccination with an H1N1 2009 pandemic influenza vaccine with or without AS03 adjuvant","volume":"205","author":"Ferguson","year":"2012","journal-title":"J Infect Dis"},{"issue":"25","key":"10.1016\/j.vaccine.2019.06.039_b0060","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1056\/NEJMoa0907650","article-title":"Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine","volume":"361","author":"Clark","year":"2009","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.vaccine.2019.06.039_b0065","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1128\/CVI.05111-11","article-title":"Immunogenicity and safety of influenza A\/H1N1 2009 inactivated split-virus vaccine in young and older adults: MF59-adjuvanted vaccine versus nonadjuvanted vaccine","volume":"18","author":"Cheong","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2019.06.039_b0070","doi-asserted-by":"crossref","first-page":"c2649","DOI":"10.1136\/bmj.c2649","article-title":"Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study","volume":"340","author":"Waddington","year":"2010","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.vaccine.2019.06.039_b0075","doi-asserted-by":"crossref","first-page":"e33723","DOI":"10.1371\/journal.pone.0033723","article-title":"Increased incidence and clinical picture of childhood narcolepsy following the 2009 H1N1 pandemic vaccination campaign in Finland","volume":"7","author":"Partinen","year":"2012","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.vaccine.2019.06.039_b0080","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1159\/000453150","article-title":"Immunogenicity and safety of pandemic influenza H5N1 vaccines in healthy adults through meta-analysis","volume":"40","author":"Guo","year":"2016","journal-title":"Cell Physiol Biochem"},{"issue":"9","key":"10.1016\/j.vaccine.2019.06.039_b0085","doi-asserted-by":"crossref","first-page":"e24384","DOI":"10.1371\/journal.pone.0024384","article-title":"Meta-analysis of the immunogenicity and tolerability of pandemic influenza A 2009 (H1N1) vaccines","volume":"6","author":"Manzoli","year":"2011","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.vaccine.2019.06.039_b0090","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1177\/0968533217723683","article-title":"The Pandemic Influenza Preparedness Framework: a viable procurement option for developing states?","volume":"17","author":"Eccleston-Turner","year":"2017","journal-title":"Med Law Int"},{"key":"10.1016\/j.vaccine.2019.06.039_b0095","unstructured":"Chan M. World now at the start of 2009 influenza pandemic. Geneva: World Health Organization; 2009. Available at: http:\/\/www.who.int\/mediacentre\/news\/statements\/2009\/h1n1_pandemic_phase6_20090611\/en\/ [accessed Sept 22, 2018]."},{"key":"10.1016\/j.vaccine.2019.06.039_b0100","doi-asserted-by":"crossref","unstructured":"Hauser M, Muscatello D, Soh A, Dwyer D, Turner R An indirect comparison meta-analysis of AS03 and MF59 adjuvants in pandemic influenza a(H1N1) PDM09 vaccines. PROSPERO 2018 CRD42018099026 Available from: http:\/\/www.crd.york.ac.uk\/PROSPERO\/display_record.php?ID=CRD42018099026.","DOI":"10.1016\/j.vaccine.2019.06.039"},{"issue":"4","key":"10.1016\/j.vaccine.2019.06.039_b0105","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.biologicals.2009.02.002","article-title":"On the relationship between mean antibody level, seroprotection and clinical protection from influenza","volume":"37","author":"Nauta","year":"2009","journal-title":"Biologicals"},{"issue":"2","key":"10.1016\/j.vaccine.2019.06.039_b0110","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/jrsm.12","article-title":"A basic introduction to fixed-effect and random-effects models for meta-analysis","volume":"1","author":"Borenstein","year":"2010","journal-title":"Res Synth Methods"},{"issue":"11","key":"10.1016\/j.vaccine.2019.06.039_b0115","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"10.1016\/j.vaccine.2019.06.039_b0120","unstructured":"Higgins JP, Deeks JJ, Altman DG, editors. 16.6.2 Indrect comparisons. In: Higgins JP, Green S, editors. Cochrane handbook for systematic reviews of interventions version 5.1.0: The Cochrane collaboration; 2011."},{"key":"10.1016\/j.vaccine.2019.06.039_b0125","unstructured":"Kirkwood B, Sterne J. Essential medical statistics, 2nd ed. Hoboken: John Wiley & Sons, Incorporated; 2003. Chapter 8, Using P-values and confidence intervals to interpret the results of statistical analyses. p. 71\u20139."},{"issue":"2","key":"10.1016\/j.vaccine.2019.06.039_b0130","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1080\/00031305.2016.1154108","article-title":"The ASA\u2019s statement on p-values: context, process, and purpose","volume":"70","author":"Wasserstein","year":"2016","journal-title":"Am Stat"},{"key":"10.1016\/j.vaccine.2019.06.039_b0135","unstructured":"Higgins JP, Altman DG, Sterne JA, editors. 8 Assessing risk of bias in included studies. In: Higgins JP, Green S, editors. Cochrane handbook for systematic reviews of interventions version 5.1.0: the Cochrane collaboration; 2011."},{"key":"10.1016\/j.vaccine.2019.06.039_b0140","unstructured":"R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2017."},{"issue":"3","key":"10.1016\/j.vaccine.2019.06.039_b0145","first-page":"40","article-title":"Meta: An R package for meta-analysis","volume":"7","author":"Schwarzer","year":"2007","journal-title":"R News"},{"issue":"7","key":"10.1016\/j.vaccine.2019.06.039_b0150","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1016\/j.vaccine.2009.12.014","article-title":"Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial","volume":"28","author":"Roman","year":"2010","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2019.06.039_b0155","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1128\/CVI.00480-10","article-title":"Effect on cellular and humoral immune responses of the AS03 adjuvant system in an A\/H1N1\/2009 influenza vaccine administered to adults during two randomised controlled trials","volume":"18","author":"Roman","year":"2011","journal-title":"Clin Vaccine Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2019.06.039_b0160","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1473-3099(10)70296-6","article-title":"Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial","volume":"11","author":"Nicholson","year":"2011","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2019.06.039_b0165","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1093\/infdis\/jis427","article-title":"Immunogenicity and safety of varying dosages of a monovalent 2009 H1N1 influenza vaccine given with and without AS03 adjuvant system in healthy adults and older persons","volume":"206","author":"Jackson","year":"2012","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2019.06.039_b0170","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/1471-2334-12-279","article-title":"A randomized, controlled non-inferiority trial comparing A(H1N1)pmd09 vaccine antigen, with and without AS03 adjuvant system, co-administered or sequentially administered with an inactivated trivalent seasonal influenza vaccine","volume":"12","author":"Langley","year":"2012","journal-title":"BMC Infect Dis"},{"issue":"40","key":"10.1016\/j.vaccine.2019.06.039_b0175","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1016\/j.vaccine.2013.07.007","article-title":"Long-term immunogenicity of an AS03-adjuvanted influenza A(H1N1)pdm09 vaccine in young and elderly adults: an observer-blind, randomized trial","volume":"31","author":"Yang","year":"2013","journal-title":"Vaccine"},{"issue":"32","key":"10.1016\/j.vaccine.2019.06.039_b0180","doi-asserted-by":"crossref","first-page":"4820","DOI":"10.1016\/j.vaccine.2012.05.013","article-title":"A randomised, single-blind, dose-range study to assess the immunogenicity and safety of a cell-culture-derived A\/H1N1 influenza vaccine in adult and elderly populations","volume":"30","author":"Hatz","year":"2012","journal-title":"Vaccine"},{"issue":"23","key":"10.1016\/j.vaccine.2019.06.039_b0185","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.1016\/j.vaccine.2012.03.017","article-title":"A randomized clinical trial to identify the optimal antigen and MF59\u00ae adjuvant dose of a monovalent A\/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects","volume":"30","author":"Hatz","year":"2012","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2019.06.039_b0190","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.4161\/hv.29393","article-title":"A dose-ranging study of MF59\u00ae-adjuvanted and non-adjuvanted A\/H1N1 pandemic influenza vaccine in young to middle-aged and older adult populations to assess safety, immunogenicity, and antibody persistence one year after vaccination","volume":"10","author":"Reisinger","year":"2014","journal-title":"Hum Vaccin Immunother"},{"issue":"8","key":"10.1016\/j.vaccine.2019.06.039_b0195","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1097\/INF.0b013e31825e6cd6","article-title":"Randomized, multicenter trial of a single dose of AS03-adjuvanted or unadjuvanted H1N1 2009 pandemic influenza vaccine in children 6 months to <9 years of age: safety and immunogenicity","volume":"31","author":"Langley","year":"2012","journal-title":"Pediatr Infect Dis J"},{"issue":"4","key":"10.1016\/j.vaccine.2019.06.039_b0200","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/infdis\/jiu173","article-title":"Relative efficacy of AS03-adjuvanted pandemic influenza A(H1N1) vaccine in children: results of a controlled, randomized efficacy trial","volume":"210","author":"Nolan","year":"2014","journal-title":"J Infect Dis"},{"issue":"9","key":"10.1016\/j.vaccine.2019.06.039_b0205","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.vaccine.2013.11.031","article-title":"An observer-blind, randomized, multi-center trial assessing long-term safety and immunogenicity of AS03-adjuvanted or unadjuvanted H1N1\/2009 influenza vaccines in children 10\u201317 years of age","volume":"32","author":"Poder","year":"2014","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2019.06.039_b0210","doi-asserted-by":"crossref","first-page":"58","DOI":"10.4161\/hv.7.1.13411","article-title":"Assessment of the safety, tolerability and kinetics of the immune response to A\/H1N1v vaccine formulations with and without adjuvant in healthy pediatric subjects from 3 through 17 years of age","volume":"7","author":"Arguedas","year":"2011","journal-title":"Hum Vaccin"},{"issue":"7","key":"10.1016\/j.vaccine.2019.06.039_b0215","doi-asserted-by":"crossref","first-page":"e92","DOI":"10.1097\/INF.0b013e318257644f","article-title":"Dose-range study of MF59-adjuvanted versus nonadjuvanted monovalent A\/H1N1 pandemic influenza vaccine in six- to less than thirty-six-month-old children","volume":"31","author":"Block","year":"2012","journal-title":"Pediatr Infect Dis J"},{"issue":"4","key":"10.1016\/j.vaccine.2019.06.039_b0220","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1097\/INF.0b013e31824b9545","article-title":"Identification of antigen and adjuvant doses resulting in optimal immunogenicity and antibody persistence up to 1 year after immunization with a pandemic A\/H1N1 influenza vaccine in children 3 to <9 years of age","volume":"31","author":"Nassim","year":"2012","journal-title":"Pediatr Infect Dis J"},{"issue":"12","key":"10.1016\/j.vaccine.2019.06.039_b0225","doi-asserted-by":"crossref","first-page":"e320","DOI":"10.1097\/INF.0000000000000462","article-title":"Immunogenicity and tolerability of an MF59-adjuvanted, egg-derived, A\/H1N1 pandemic influenza vaccine in children 6\u201335 months of age","volume":"33","author":"Knuf","year":"2014","journal-title":"Pediatr Infect Dis J"},{"issue":"2","key":"10.1016\/j.vaccine.2019.06.039_b0230","doi-asserted-by":"crossref","first-page":"358","DOI":"10.4161\/21645515.2014.987014","article-title":"Immunogenicity and safety of cell-derived MF59\u00ae-adjuvanted A\/H1N1 influenza vaccine for children","volume":"11","author":"Knuf","year":"2015","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"10.1016\/j.vaccine.2019.06.039_b0235","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.vaccine.2014.10.085","article-title":"Safety and immunogenicity of an MF59\u00ae-adjuvanted A\/H1N1 pandemic influenza vaccine in children from three to seventeen years of age","volume":"33","author":"Knuf","year":"2015","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2019.06.039_b0240","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1080\/02664763.2012.700448","article-title":"Heterogeneity and study size in random-effects meta-analysis","volume":"40","author":"Bowater","year":"2013","journal-title":"J Appl Stat"},{"key":"10.1016\/j.vaccine.2019.06.039_b0245","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.smrv.2017.06.006","article-title":"Incidence of narcolepsy after H1N1 influenza and vaccinations: Systematic review and meta-analysis","volume":"38","author":"Sarkanen","year":"2018","journal-title":"Sleep Med Rev"},{"key":"10.1016\/j.vaccine.2019.06.039_b0250","unstructured":"World Health Organization. Influenza A (H1N1) 2009 pandemic vaccine and narcolepsy. 2016. Available at: http:\/\/www.who.int\/vaccine_safety\/committee\/topics\/influenza\/pandemic\/h1n1_safety_assessing\/Dec-2015\/en\/ [accessed Sept 22 2018])."},{"issue":"41","key":"10.1016\/j.vaccine.2019.06.039_b0255","doi-asserted-by":"crossref","first-page":"6202","DOI":"10.1016\/j.vaccine.2018.08.008","article-title":"Narcolepsy and adjuvanted pandemic influenza A (H1N1) 2009 vaccines\u2013Multi-country assessment","volume":"36","author":"Weibel","year":"2018","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.vaccine.2019.06.039_b0260","doi-asserted-by":"crossref","first-page":"e108489","DOI":"10.1371\/journal.pone.0108489","article-title":"Risk of narcolepsy associated with inactivated adjuvanted (AS03) A\/H1N1 (2009) pandemic influenza vaccine in Quebec","volume":"9","author":"Montplaisir","year":"2014","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.vaccine.2019.06.039_b0265","doi-asserted-by":"crossref","first-page":"e114361","DOI":"10.1371\/journal.pone.0114361","article-title":"Antigenic differences between AS03 adjuvanted influenza A (H1N1) pandemic vaccines: implications for pandemrix-associated narcolepsy risk","volume":"9","author":"Vaarala","year":"2014","journal-title":"PLoS One"},{"issue":"294","key":"10.1016\/j.vaccine.2019.06.039_b0270","doi-asserted-by":"crossref","first-page":"294ra105","DOI":"10.1126\/scitranslmed.aab2354","article-title":"Antibodies to influenza nucleoprotein cross-react with human hypocretin receptor 2","volume":"7","author":"Ahmed","year":"2015","journal-title":"Sci Transl Med"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19308011?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19308011?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:33:20Z","timestamp":1759401200000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19308011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":54,"journal-issue":{"issue":"31","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S0264410X19308011"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.06.039","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An indirect comparison meta-analysis of AS03 and MF59 adjuvants in pandemic influenza A(H1N1)pdm09 vaccines","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.06.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}